AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Tekla Healthcare Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC.
The fund invests in public equity markets across the globe.
It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries.
The fund primarily invests in growth stocks of small cap companies.
It employs fundamental analysis with a focus on factors such as current or anticipated market position for services or products, experienced business management, recognized technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio.
The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index.
It was previously known as H&Q Healthcare Investors.
Tekla Healthcare Investors was formed on October 31, 1986 and is domiciled in the United States.
Country | United States |
IPO Date | Apr 23, 1987 |
Industry | Asset Management |
Sector | Financial Services |
Employees | n/a |
CEO | Dr. Daniel R. Omstead M.S, Ph.D. |
Contact Details
Address: 100 Federal Street Boston, Massachusetts United States | |
Website | https://www.teklacap.com/hqh.html |
Stock Details
Ticker Symbol | HQH |
Exchange | NYSE |
Fiscal Year | October - September |
Reporting Currency | USD |
CIK Code | 0000805267 |
CUSIP Number | 87911J103 |
ISIN Number | US87911J1034 |
Employer ID | 04-6564285 |
SIC Code |
Key Executives
Name | Position |
---|---|
Christopher F. Brinzey MBA | Senior Vice President of Research and Portfolio Manager |
Dr. Daniel R. Omstead M.S, Ph.D. | Portfolio Manager |
Dr. Frank T. Gentile Ph.D. | Senior Vice President of Research and Portfolio Manager |
Dr. Jason C. Akus M.B.A., M.D., MBA | Vice President of Research and Portfolio Manager |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 20, 2024 | 3 | Filing |
Dec 20, 2024 | 3 | Filing |
Dec 16, 2024 | N-CEN | Filing |
Dec 09, 2024 | N-CSR | Filing |
Nov 27, 2024 | NPORT-P | Filing |
Nov 18, 2024 | SC 13D/A | [Amend] Filing |
Oct 22, 2024 | SC 13D/A | [Amend] Filing |
Sep 03, 2024 | N-PX | Filing |
Aug 28, 2024 | NPORT-P | Filing |
Aug 15, 2024 | 40-17G | Filing |